Bibliography
- VANE JR: The fight against rheumatism:from willow bark to COX-1 sparing drugs. Physiol. Pharmacol. (2000) 51:573–586.
- MARNETT LJ: Cyclooxygenase mechanisms. Curr. Opin. Chem. Biol. (2000) 4:545–552.
- CHANDRASEKHARAN NV, DAI H, ROOS KL et al.: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/ antipyretic drugs: cloning, structure, and expression. Proc. Nati Acad. Li. USA (2002) 99:13926–13932.
- DE LEVAL X, JULEMONT F, BENOIT V, FREDERICH M, PIROTTE B, DOGNE J-M: First and second generation COX-2 selective inhibitors Minirev. Med. Chem. (2004) 4:597–602.
- FITZGERALD GA, PATRONO C: The coxibs, selective inhibitors of cyclooxygenase-2. N Engl. J. Med. (2001) 345:433–442.
- FLOWER RJ: The development of COX-2inhibitors. Nat. Rev Drug Discov. (2003) 2:179–191.
- SUBBARAMAIAH K, DANNENBERG AJ: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci (2003) 24:96–102.
- ZWEIFEL BS, DAVIS TW, ORNBERG RL, MASFERRER JL: Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res. (2002) 62:6706–6711.
- KUNDU N, SMYTH MJ, SAMSEL L, FULTON AM: Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Res. Treat. (2002) 76:57–64.
- WANG Z, FUENTES CF, SHAPSHAY SM: Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope (2002) 112:839–843.
- STRATTON MS, ALBERTS DS: Current application of selective COX-2 inhibitors in cancer prevention and treatment. Oncology (2002) 16\(Supp1.4):37–51.
- ORENGO IF, GERGUIS J, PHILLIPS R, GUEVARA A, LEWIS AT, BLACK HS: Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model. Arch. Dermatoi (2002) 138:751–755.
- PHILLIPS RK, WALLACE MH, LYNCH PM et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut (2002) 50:857–860.
- WASKEWICH C, BLUMENTHAL RD, LI H, STEIN R, GOLDENBERG DM, BURTON J: Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. (2002) 62:2029–2033.
- MANN JR, DUBOIS RN: Cyclooxygenase -2 and gastrointestinalcancer. Cancer J. (2004) 10:145–152.
- KOEHNE CH, DUBOIS RN: COX-2 inhibition and colorectal cancer. Semin. Oncol. (2004) 31 (Supp1.7) :12–21.
- BROWN JR, DUBOIS RN: Cyclooxygenase as a target in lung cancer. Clin. Cancer Res. (2004) 10:4266–4269.
- CROSBY CG, DUBOIS RN: The cyclooxygenase-2 pathway as a target for treatment or prevention of cancer. Expert Opin. Emerg. Drugs (2003) 8:1–7.
- NAKANISHI Y, KAMIJO R, TAKIZAWA K, HATORI M, NAGUMO M: Inhibitors of cyclooxygenase -2 (COX-2) suppressed the proliferation and differentiation of human leukaemia cell lines. Eur. I Cancer (2001) 37:1570–1578.
- WEBER A, CASINI A, HEINE A, KUHN D, SUPURAN CT, SCOZZAFAVA A, KLEBE G: Unexpected nanomolar inhibition of carbonic anhydrase by COX-2 selective Celecoxib: new pharmacological opportunities due to related binding site recognition. J. Med. Chem. (2004) 47:550–557.
- SUPURAN CT, CASINI A, MASTROLORENZO A, SCOZZAFAVA A: COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. Minirev. Med. Chem. (2004) 4:625–632.
- CASINI A, SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Sulfonamides and sulfonylated derivatives as anticancer agents. Curr. Cancer Drug Targ. (2002) 2:55–75.
- SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors: aromatic sulfonamides and disulfonamides act as efficient tumor growth inhibitors. J. Enz. Inhib. (2000) 15:597–610.
- SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors — part 94. 1, 3,4-Thiadiazole-2-sulfonamide derivatives as antitumor agents? Eur: J. Med. Chem. (2000) 35:867–874.
- PASTOREKOVA S, PASTOREK J: Cancer-related carbonic anhydrase isozymes and their inhibition. In: Carbonic Anhydrase — Its inhibitors and Activators. Supuran CT Scozzafava A, Conway J (Eds), CRC Press, Boca Raton (FL), USA, (2004):253–280.
- ••Excellent review on the involvement ofCAs in tumorigenesis, and their inhibition as means of therapeutic use of sulfonamides targeting the tumour-associated CA isozymes IX and XII.